Pancreatic Stem Cells High Impact Factor Journals

 One of the major pancreatic diseases, diabetes mellitus is a metabolic disorder caused by having an insufficient number of insulin-producing β cells.  Humanity has witnessed a pandemic in late December or, early January. Novel corona virus nCov-19 is responsible for causing COVID-19. The first case was reported in Wuhan city, China in the month of December 2019. No specific drugs have been approved yet for its treatment, though, convalescent plasma (CP) therapy is expected to increase the survivable rate. The history of convalescent plasma therapy dates back to the early 20th century. A plethora of studies suggest that CP can be used to treat the emerging infectious diseases. We had a systematic search in PubMed and found numerous Chinese and Korean clinical trials of convalescent plasma transfusions. The present review gives an insight in to the same. Experimental induction of embryonic stem cells (ESCs) to become pancreatic β cells can potentially provide ample resource for cell transplantation therapy of type I diabetes mellitus. Moreover, it has been indicated that the insulin staining of ESC progeny was insulin uptake from the culture medium. Here we show that a simple three‐step experimental approach based on the combination induction by activin A, all‐trans retinoic acid, and other mature factors is able to induce murine ESCs to differentiate into insulin‐producing cells in 2 weeks, and that insulin release of these induced cells is regulated by the glucose concentration.  The findings reported here offer a novel in vitro model to study the differentiation mechanism of pancreatic β cells and a potential source of insulin‐producing cells for transplantation therapy of type I diabetes mellitus.  

High Impact List of Articles

Relevant Topics in Medical